Login Partner With Us

JADPRO
The ASCO Post
JNCCN

From the Journal
- Online First
Issues
Sections
Topics & Conditions
Solid Tumors
Hematologic Malignancies
Issues in Oncology
Supportive Care
Developmental Therapeutics
Events
Live Events
- JADPRO Live
Webinars
- JADPRO Clinical Case Series
Education
Educational Resources
Multimedia
- Podcasts
- Videos
About

Submissions Subscribe

JADPRO / CME Supplements / Volume 6, Supplement 1 (Mar/Ap... / Questions Answered About Uridine Triacetate

Meeting Abstracts Volume 6, Supplement 1 (Mar/Apr 2015)

Questions Answered About Uridine Triacetate

Volume 6, Supplement 1 (Mar/Apr 2015)

Share

You must be signed in to view this page

Advertisement

Current Issue

Nov/Dec 2024 Cover

Nov/Dec 2024 Cover Art

Vol 15 No 7 Nov/Dec 2024

Immediate Patient Access to Test Results and the Impact on Advanced Practitioners

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO

November 26, 2024

Obinutuzumab Infusion-Related Reactions Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors

Erin Hickey Zacholski, PharmD, BCOP, Sarah Rugh, PharmD Candidate, Jenna Marshall, PharmD Candidate, Et al.

November 26, 2024

Pancreatic Cancer The Advanced Practitioners Role in Early Diagnosis and Management

Lindsay Knox, FNP-C

November 26, 2024

Table of Contents Archive

Recent Issues

Volume 15, Number 7 (Nov/Dec 2024)

Volume 15, Number 6 (Sep/Oct 2024)

Volume 15, Number 5 (Jul/Aug 2024)

Volume 15, Number 4 (May/Jun 2024)

Submissions Subscribe

About

About Us
Society
Terms and Conditions
Privacy Policy
Advertise With JADPRO

Membership

Login

Conexiant Oncology Publications

The ASCO Post
JNCCN
JNCCN 360

Copyright © 2024 Conexiant unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.